Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature

Clinical Therapeutics

Volumn 38, Issue 7, 2016, Pages 1696-1709

  Wong, Bruce ^a   Kruse, Gregory ^b   Kutikova, Lucie ^c   Ray, Kausik K ^d   Mata, Pedro ^e   Bruckert, Eric ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c AMGEN INC   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e Fundación Hipercoesterolaemia Familiar   (Spain)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

bias; cardiovascular disease; familial hypercholesterolemia; lipid modifying therapy; risk

Indexed keywords

ANTILIPEMIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DENMARK; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY; HEART INFARCTION; HOSPITAL; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MEDICAL LITERATURE; MEDLINE; NETHERLANDS; NORWAY; OUTCOME ASSESSMENT; POPULATION; PRIMARY PREVENTION; PUBLICATION; REGISTER; RISK ASSESSMENT; SECONDARY PREVENTION; SELECTION BIAS; SPAIN; SYSTEMATIC REVIEW; UNITED KINGDOM; CARDIOVASCULAR DISEASES; COMPLICATION; RISK;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RISK;

EID: 84973523741     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.05.006     Document Type: Article

References (30)

1. 1 Austin, M.A., Hutter, C.M., Zimmern, R.L., et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review. Am J Epidemiology 160 (2004), 407–420.
2. 2 Najam, O., Ray, K.K., Familial hypercholesterolemia: a review of the natural history, diagnosis, and management. Cardiol Ther 4 (2015), 25–38.
3. 3 Libby, P., Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003), 3A–6A.
4. 4 Robinson, J.G., Goldberg, A.C., Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:3 Suppl (2011), S18–S29.
5. 5 Ned, R.M., Sijbrands, E.J.G., Cascade screening for familial hypercholesterolemia (FH). PLoS Currents, 2011, 3 RRN1238.
6. 6 Elis, A., Zhou, R., Stein, E.A., Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 108 (2011), 223–226.
7. 7 Talmud, P.J., Shah, S., Whittall, R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 381 (2013), 1293–1301.
8. 8 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490.
9. 9 Alonso, R., Andres, E., Mata, N., et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 63 (2014), 1982–1989.
10. 10 Allard, M.D., Saeedi, R., Yousefi, M., et al. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis, 13, 2014, 65.
11. 11 Hill, J.S., Hayden, M.R., Frohlich, J., et al. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vas Bio 11 (1991), 290–297.
12. 12 Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
13. 13 Wells GA, Shea B, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed: May 25, 2016.
14. 14 Benn, M., Watts, G.F., Tybjaerd-Hansen, A., et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrin Metab 97 (2012), 3956–3964.
15. 15 Mabuchi, H., Koizumi, J., Shimizu, M., et al. Development of coronary heart disease in familial hypercholesterolemia. Circulation 79 (1989), 225–232.
16. 16 Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee. BMJ 303 (1991), 893–896.
17. 17 Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee. Atherosclerosis 142 (1999), 105–112.
18. 18 Alonso, R., Mata, N., Castillo, S., et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 200 (2008), 315–321.
19. 19 Neil, A., Cooper, J., Betteridge, J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 29 (2008), 2625–2633.
20. 20 Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
21. 21 Besseling, J., Kindt, I., Hof, M., et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 233 (2014), 219–223.
22. 22 Mundal, L., Sarancic, M., Ose, L., et al. Mortality among patients with familial hypercholesterolaemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc, 3, 2014, e001236.
23. 23 Jensen, J., Blankenhorn, D.H., Kornerup, V., Coronary disease in familial hypercholesterolemia. Circulation 36 (1967), 77–82.
24. 24 Slack, J., Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2 (1969), 1380–1382.
25. 25 Sijbrands, E.J., Westendorp, R.G., Paola Lombardi, M., et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 149 (2000), 421–425.
26. 26 Sijbrands, E.J., Westendorp, R.G., Defesche, J.C., et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322 (2001), 1019–1023.
27. 27 Mohrschladt, M.F., Westendorp, R.G.J., Leuven, J.A.G., et al. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 172 (2004), 329–335.
28. 28 Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25 (2010), 603–605.
29. 29 Benn, M., Watts, G.F., Tybjaerg-Hansen, A., Nordestgaard, G.B., Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 37 (2016), 1384–1394.
30. 30 Lo, C.K., Mertz, D., Loeb, M., Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol, 14, 2014, 45.